Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Super Hi-TCR-T Cells for Advanced HCC and Solid Tumors
NCT06902389Phase 2Recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jul 2025
- Primary completion
- Jan 2028
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in hepatocellular carcinoma (HCC) and solid tumor, sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoints: Progression-Free Survival at 12 months and Adverse Events at 12 months. Started Jul 2025; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)solid tumor
Beyond the preview
Go deeper on NCT06902389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902389.